celecoxib has been researched along with Arthritis, Juvenile in 8 studies
Arthritis, Juvenile: Arthritis in children, with onset before 16 years of age. The terms juvenile rheumatoid arthritis (JRA) and juvenile idiopathic arthritis (JIA) refer to classification systems for chronic arthritis in children. Only one subtype of juvenile arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We know from adult randomised controlled trials that some NSAIDs, such as ibuprofen, naproxen, and aspirin, can be effective in certain chronic pain conditions." | 4.95 | Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents. ( Anderson, B; Cooper, TE; Eccleston, C; Fisher, E; Wilkinson, NM, 2017) |
| " PK and efficacy data from a randomized, double-blind, 12-week study of celecoxib dosed at 3 and 6 mg/kg twice a day (bid) as an investigational suspension formulation in 152 JRA patients aged 2 to 17 years, PK data from 36 adult RA patients, and relative bioavailability data in healthy adults comparing suspension or capsule sprinkles with the commercial capsule were analyzed." | 2.77 | Dosing celecoxib in pediatric patients with juvenile rheumatoid arthritis. ( Bello, A; Bloom, BJ; Hutmacher, MM; Krishnaswami, S; Robbins, JL; West, C, 2012) |
| "Both celecoxib doses were at least as effective as naproxen at Week 12 [ACR Pediatric-30 treatment differences: celecoxib 3 mg/kg bid-naproxen=1." | 2.74 | A prospective study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritis. ( Bloom, BJ; Foeldvari, I; Giannini, EH; Krishnaswami, S; Lovell, DJ; Robbins, JL; Steidle, G; Szer, IS; West, CR; Zemel, LS, 2009) |
| "Juvenile toxicology studies in animals provide useful information to guide monitoring of potential adverse effects in children especially on growth and development." | 2.45 | Essentials for starting a pediatric clinical study (4): Clinical pediatric safety planning based on preclinical toxicity studies and pediatric pharmacovigilance guidance. ( Sheth, N, 2009) |
| " All adverse events (AEs) regardless of severity were captured in the database." | 1.40 | Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the Phase 4 registry. ( Abramsky, S; Brunner, HI; Chalom, EC; Giannini, EH; Goldsmith, DP; Gottlieb, BS; Jung, LK; Lovell, DJ; Morris, PW; Nanda, K; Onel, KB; Petiniot, L; Shishov, M; Sobel, RE; Weiss, JE; Young, JP, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Malik, A | 1 |
| Stringer, E | 1 |
| Warner, N | 1 |
| van Limbergen, J | 1 |
| Vandersteen, A | 1 |
| Muise, A | 1 |
| Derfalvi, B | 1 |
| Eccleston, C | 1 |
| Cooper, TE | 1 |
| Fisher, E | 1 |
| Anderson, B | 1 |
| Wilkinson, NM | 1 |
| Sobel, RE | 1 |
| Lovell, DJ | 2 |
| Brunner, HI | 1 |
| Weiss, JE | 1 |
| Morris, PW | 1 |
| Gottlieb, BS | 1 |
| Chalom, EC | 1 |
| Jung, LK | 1 |
| Onel, KB | 1 |
| Petiniot, L | 1 |
| Goldsmith, DP | 1 |
| Nanda, K | 1 |
| Shishov, M | 1 |
| Abramsky, S | 1 |
| Young, JP | 1 |
| Giannini, EH | 2 |
| Foeldvari, I | 1 |
| Szer, IS | 1 |
| Zemel, LS | 1 |
| Robbins, JL | 2 |
| West, CR | 1 |
| Steidle, G | 1 |
| Krishnaswami, S | 2 |
| Bloom, BJ | 2 |
| Sheth, N | 1 |
| Hutmacher, MM | 1 |
| Bello, A | 1 |
| West, C | 1 |
| Young, D | 1 |
| Cummins, R | 1 |
| Wagner-Weiner, L | 1 |
| Paller, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| SINCERE™: Safety in Idiopathic Arthritis: NSAIDs and Celebrex Evaluation Registry A Prospective Observational Registry Of Patients With Juvenile Idiopathic Arthritis (JIA) Treated With NSAIDs[NCT00688545] | 275 participants (Actual) | Observational | 2009-04-30 | Terminated (stopped due to See termination reason in detailed description.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
JIA medications by class: GI protective agents (eg, proton-pump inhibitors, antacids, surcalfate), other GI, DMARDs, biologics, antihypertensives, NSAIDs (Celecoxib, Diclofenac, Ibuprofen, Meloxicam, Naproxen, other NSAIDs), corticosteroids (oral, IV, intra-articular, other forms), analgesics Acetaminophen, Opioids, other). Participants could receive more than 1 medication. (NCT00688545)
Timeframe: Year 2 or early termination
| Intervention | Participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GI protective agents | Other GI | DMARDs | Biologics | Antihypertensives | NSAIDs (Celecoxib) | NSAIDs (Diclofenac) | NSAIDs (Ibuprofen) | NSAIDs (Meloxicam) | NSAIDs (Naproxen) | NSAIDs (Other) | Corticosteroids (oral, IV, intra-articular) | Corticosteroids (Other) | Analgesics (Acetaminophen, Opioids, Other) | |
| Celecoxib | 20 | 5 | 24 | 13 | 1 | 7 | 0 | 1 | 1 | 0 | 0 | 4 | 2 | 11 |
| nsNSAIDs | 54 | 8 | 102 | 60 | 4 | 2 | 0 | 9 | 8 | 7 | 3 | 15 | 6 | 19 |
Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Participants with multiple occurrences of an AE within a category were counted once within the category. AEs attributed to the NSAID (celecoxib or nsNSAID) utilized at time of event, regardless of the initial NSAID treatment at Registry entry. (NCT00688545)
Timeframe: Baseline up to 2 years
| Intervention | Participants (Number) | |
|---|---|---|
| AEs | SAEs | |
| Celecoxib | 36 | 2 |
| nsNSAIDs | 117 | 9 |
2 reviews available for celecoxib and Arthritis, Juvenile
| Article | Year |
|---|---|
Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Arthritis, Rheumatoid; Asp | 2017 |
Essentials for starting a pediatric clinical study (4): Clinical pediatric safety planning based on preclinical toxicity studies and pediatric pharmacovigilance guidance.
Topics: Adverse Drug Reaction Reporting Systems; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis | 2009 |
2 trials available for celecoxib and Arthritis, Juvenile
| Article | Year |
|---|---|
A prospective study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritis.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Celecoxib; Child; Child, P | 2009 |
Dosing celecoxib in pediatric patients with juvenile rheumatoid arthritis.
Topics: Adolescent; Arthritis, Juvenile; Capsules; Celecoxib; Child; Child, Preschool; Dose-Response Relatio | 2012 |
4 other studies available for celecoxib and Arthritis, Juvenile
| Article | Year |
|---|---|
Multisystem Autoimmune Inflammatory Disease, Including Colitis, Due to Inborn Error of Immunity.
Topics: Adolescent; Agammaglobulinemia; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Autoim | 2021 |
Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the Phase 4 registry.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Celecoxib; Child; Child, P | 2014 |
FDA advisers endorse Celebrex for juvenile rheumatoid arthritis: lack of studies in children raises safety concerns.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Biomedical Research; Celec | 2007 |
Pseudoporphyria induced by celecoxib in a patient with juvenile rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Celecoxib; Child; Cyclooxygenase 2; Fe | 2000 |